Advanced Health Intelligence Ltd. (NASDAQ:AHI) Short Interest Down 16.7% in February

Advanced Health Intelligence Ltd. (NASDAQ:AHI – Get Rating) saw a significant drop in short interest in the month of February. As of February 28th, there was short interest totalling 82,400 shares, a drop of 16.7% from the February 13th total of 98,900 shares. Based on an average daily volume of 208,100 shares, the short-interest ratio is presently 0.4 days.

Institutional Trading of Advanced Health Intelligence

Several institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC acquired a new position in Advanced Health Intelligence in the 1st quarter valued at $29,000. Jane Street Group LLC purchased a new stake in shares of Advanced Health Intelligence during the first quarter worth $33,000. OLD Mission Capital LLC purchased a new position in shares of Advanced Health Intelligence in the third quarter worth about $37,000. Finally, Susquehanna International Group LLP acquired a new position in Advanced Health Intelligence during the fourth quarter worth about $58,000. Institutional investors and hedge funds own 1.15% of the company’s stock.

Advanced Health Intelligence Trading Down 3.4 %

Advanced Health Intelligence stock opened at $0.40 on Monday. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.90 and a quick ratio of 3.40. The company’s fifty day moving average price is $0.48 and its 200 day moving average price is $0.53. Advanced Health Intelligence has a 1 year low of $0.35 and a 1 year high of $2.08.

Advanced Health Intelligence Company Profile

(Get Rating)

Advanced Health Intelligence Ltd. operates as a mobile application and technology development company in Australia and internationally. It develops and patents BodyScan, a proprietary measurement/dimensioning technology that enables end-user to check and assess body dimensions using a smartphone. The company also provides FaceScan for measuring vital signs, and risks associated with cardiovascular disease, heart attack, and stroke; and DermaScan, a dermatological scanner.